Neurotrauma Sciences’ Focus: Stroke and TBI patients are large, underserved populations compared to high impact neurologic diseases.
Major Technological advances ENABLE FUTURE SUCCESS IN STROKE AND TBI clinical trials
Hover over the boxes to learn how NTS will utilize these advances to revolutionize Stroke and TBI clinical trials.
Computed Tomographic Angiography (CTA) and Computed Tomographic Perfusion (CTP)
Computed Tomographic Angiography (CTA) and Computed Tomographic Perfusion (CTP) are now standard of care and provide critical diagnostic information on blood vessels and brain tissue to target specific patient populations.
Mechanical thrombectomy (MT) is a minimally invasive procedure using specialized catheters to remove a clot. MT represents a major advancement in the treatment of stroke. NTS clinical trials will study the adjunctive effects of NTS-104 in patients undergoing an MT procedure.
Blood-based biomarkers assays have been recently approved by the FDA for the diagnosis of TBI. NTS will utilize these assays, along with physiological assessments and imaging techniques to identify optimal patient populations and assess longitudinal outcomes.
TRACK-TBI (U.S.) and CENTER-TBI (Europe) have generated the first longitudinal TBI databases (total = 7,500 patients) and clinical trial infrastructures. NTS has utilized these databases to identify mild TBI sub-populations, enabling optimized clinical trial design.